Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (468)	4/2/2003 1:16:21 PM
From: nigel bates	Read Replies (1) of 897

Just making the suggestion. My knowledge is towards the thin film end of shallow. I would guess that they could do some kind of Trickle deal on the hepatocytes relatively quickly, but I doubt that justifies the current excitement. "This discovery serves as a foundation for the commercialization of hESC-based cell types for drug discovery applications," stated Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "Both large pharmaceutical companies and small biotechs would benefit from the availability of hepatocytes derived from hESCs that can reliably represent a functioning liver. We have already received two U.S. patents covering hESC-derived hepatocytes and their use as drug screening tools (U.S. Patent Nos. 6,458,589 and 6,506,574). Our next steps are to complete the characterization of these cells and to develop a high volume production process. At that point we have a product."...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next